Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2013

View Archived Issues

Serum albumin binding proteins developed at Ablynx

Serine racemase knockout mice show decreased susceptibility to seizures

Pharma Bio partners timodepressin in Russia

NanoSmart and UCLA collaborate on new drug delivery platform

Innate Pharma presents phase I results for their anti-KIR antibody in AML

Novel radiotracers for imaging tau pathology evaluated

New antineoplastic agents synthesized at Pharminox

French researchers disclose new monoclonal antibodies for cancer and other disorders

ArQule patents new protein kinase inhibitors for cancer

Enrollment in phase II GMI-1070 trial in sickle cell disease completed

Novel thrombin inhibitors divulged by Chinese researchers

Iluvien receives marketing approval for chronic diabetic macular edema in Spain

Scientists at Kissei Pharmaceutical synthesize new SGLT2 inhibitors

Xencor receives milestone payment from Janssen for Xtend antibody

Boehringer Ingelheim enrolls patients in phase III HCVerso program

Medicago signs loan agreement with major pharmaceutical company

Siemens presents early clinical results for [18F]-T-807

Kyorin and Daiichi Sankyo terminate imidafenacin agreement in Brazil

Emergent BioSolutions begins phase II trial of NuThrax anthrax vaccine

Data and safety monitoring board clears way to completion for SyNAPSe trial

European CHMP hands down negative opinion for Raxone MAA

FDA approves first patch for treatment of migraine

European CHMP set to discuss MAA for defibrotide

Omeros' CRA technology identifies small molecules for Class B GPCR

Phase I study of KPT-330 opens to patients with AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...